Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars Bengaluru, Karnataka, India, July 7, 2025  Biocon Biologics Ltd (BBL), a fully integrated global biosimilars ...

Objectives Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognised as one of the most challenging symptoms to manage. The existence of multiple ...

This essay examines the implications of the COVID-19 pandemic for health inequalities. It outlines historical and contemporary evidence of inequalities in pandemics—drawing on international research ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that ...

We estimate that 418 million disability-adjusted life years (DALYs) could be attributable to mental disorders in 2019 (16% of global DALYs)—a more than three-fold increase compared to conventional ...

The gut microbiota is now considered as one of the key elements contributing to the regulation of host health. Virtually all our body sites are colonised by microbes suggesting different types of ...

Kota Kinabalu member of parliament Datuk Chan Foong Hin has called on the Federal Government and the Ministry of Health to ...

Objectives To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Methods An ...

Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III. (2014). doi: 10.1182/blood.V124.21.3612.3612 Crossref Full Text | Google Scholar 131. Peng Y, Li F, Zhang P, Wang X, Shen Y, ...

June 23, 2025 KATHMANDU – The government has allocated Rs21.1 million to launch preventive measures against non-communicable diseases (NCDs), which account for 73 percent of the country’s total deaths ...

Introduction In patients with chronic obstructive pulmonary disease (COPD), the risk of certain cardiovascular (CV) events is increased by threefold to fivefold in the year following acute ...